Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 Jul 05 | 2022UPDATED: Indications Table for CD19 CAR-T US Approvals and SubmissionsAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jun 29 | 2022Thoughts on Breyanzi’s FDA Approval in 2L LBCLAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jun 28 | 2022The EC Grants Yescarta Marketing Authorization for ≥4L R/R FLAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 24 | 2022Breyanzi Receives FDA Approval for 2L LBCLAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19, Topics Jun 24 | 2022Breyanzi Could Receive a CHMP Opinion for 2L LBCL (TI) as Early as September 2022; Yescarta in 2L LBCL and Tecartus in R/R ALL Absent from June’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Jun 22 | 2022Spotlight on Poseida’s CAR-T StrategyAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 20 | 2022Breyanzi Starts EMA Assessment in 2L LBCL (TI); Tecartus and Yescarta Absent from June's CHMP AgendaAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Jun 15 | 2022Autolus Presents Updated Results for Obe-cel, AUTO1/22, and AUTO4; Autolus’s EHA 2022 Investor Event; Academic BCMA CAR-T ARI0002h Reports Encouraging Efficacy in R/R MM; EHA 2022 Final AnalysisAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 14 | 2022Gracell Presents Updated Results for GC012F and GC502; Gracell’s EHA 2022 Investor Event; EHA 2022 Analysis 2Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T, CD19 Jun 13 | 2022Novartis Presents Updated Results for T-Charge Assets PHE885 and YTB323; A Comparative Analysis Demonstrates Kymriah’s Safety Superiority Over Yescarta in R/R FL; EHA 2022 Analysis 1Access Free Blast
Free
Posted in: Autologous, CAR-T, TCR Jun 10 | 2022Adaptimmune and GSK Present Updated Results from Afami-cel and Lete-cel ; CARsgen’s CT041 Demonstrates Clinical Efficacy in Gastric Cancer; First Clinical Data from Carisma’s CT-0508; ASCO 2022 Final AnalysisAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Jun 09 | 2022PBCAR0191 Reports Improved Efficacy in CAR-T Relapse Patients; Precision to Evaluate PBCAR0191 with sLD; Updated Milestones for PBCAR19B and PBCAR269A; Precision Mid-Year 2022 EventAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 09 | 2022Novel CAR-T Assets in MM; Arcellx, Gracell, and OriCell Present Updated Clinical Results in R/R MM; ASCO 2022 Analysis 4Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jun 08 | 2022CARTITUDE-1 and CARTITUDE-2 Study Updates; Carvykti Demonstrates Durable Responses at 2-Year Follow-Up; Legend Reports Delayed Cases of Parkinsonism; ASCO 2022 Legend Investor EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 07 | 2022Gilead (Kite) and 2seventy Bio Present Study Designs for their Next-Generation Assets Targeting Hematologic Malignancies; ASCO 2022 Analysis 3Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 06 | 2022Initial Data from Yescarta’s Ph2 ZUMA-14 Study for R/R LBCL in Combination with Rituximab; Updated Results for Tecartus in ALL and MCL; ASCO 2022 Analysis 2Access Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 05 | 2022The Race Continues in the 2L LBCL Setting; BMS and Gilead Provide Clinical Updates for Breyanzi and Yescarta; ASCO 2022 Analysis 1Access Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jun 04 | 2022Thoughts on Carvykti’s EC Conditional Marketing Authorization in ≥4L r/r MMAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Jun 01 | 2022Carvykti Meets Another Regulatory Milestone; LB1901’s FDA Clinical Hold Lifted; Legend Q1 2022 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 May 27 | 2022Kymriah Receives FDA Approval for R/R FL After Two or More Lines of Systemic TherapyAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.